Symptom Perception
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03646669 |
|
Recruitment Status :
Enrolling by invitation
First Posted : August 24, 2018
Last Update Posted : March 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Asthma | Behavioral: PEF Feedback Behavioral: Asthma education | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Health Services Research |
| Official Title: | Symptom Perception, Behavior, and Outcomes in Older Asthmatics |
| Actual Study Start Date : | February 15, 2019 |
| Estimated Primary Completion Date : | April 2022 |
| Estimated Study Completion Date : | April 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Asthma education and PEF feedback
Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
|
Behavioral: PEF Feedback
Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
Other Name: Intervention Arm |
|
Placebo Comparator: Asthma education
No PEF feedback arm
|
Behavioral: Asthma education
General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device. |
- Change in Beliefs about Illness Perception Questionnaire (BIPQ) [ Time Frame: 1 months after intervention ]BIPQ includes 9 items for each of the 5 cognitive domains designed to rapidly assess the cognitive and emotional representations of illness. Each item is scored on a 0 (none) to 10 (extreme). Items on the BIPQ are not meant to be summed, but rather evaluated and interpreted individually.
- Change in Beliefs about Illness Perception Questionnaire (BIPQ) [ Time Frame: 2 months after intervention ]BIPQ includes 9 items for each of the 5 cognitive domains designed to rapidly assess the cognitive and emotional representations of illness. Each item is scored on a 0 (none) to 10 (extreme). Items on the BIPQ are not meant to be summed, but rather evaluated and interpreted individually.
- Change in PEF [ Time Frame: 1 month after intervention ]Assessed based on alignment of patient guesses and actual PEF values recorded by the AM2 device.
- Change in PEF [ Time Frame: 2 months after intervention ]Assessed based on alignment of patient guesses and actual PEF values recorded by the AM2 device.
- Change in Beliefs about Medicines Questionnaire (BMQ) [ Time Frame: 1 month after intervention ]10-item scale that measures beliefs about asthma controller medication in 2 subdomains: necessity and concerns. All items have a five-point Likert answer option, ranging from 1 = strongly disagree to 5 = strongly agree, with total range from 5 to 50, with higher scores indicate stronger beliefs about the corresponding concepts.
- Change in Beliefs about Medicines Questionnaire (BMQ) [ Time Frame: 2 months after intervention ]10-item scale that measures beliefs about asthma controller medication in 2 subdomains: necessity and concerns. All items have a five-point Likert answer option, ranging from 1 = strongly disagree to 5 = strongly agree, with total range from 5 to 50, with higher scores indicate stronger beliefs about the corresponding concepts.
- Change in Medication Adherence Rating Scale (MARS) [ Time Frame: 1 month after intervention ]MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence.
- Change in Medication Adherence Rating Scale (MARS) [ Time Frame: 2 months after intervention ]MARS is a self-reported questionnaire with the total score range from 0-10 with a higher score indicating better adherence.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥60 years
- English or Spanish speaking
- Asthma diagnosis made by a health care provider
Exclusion Criteria:
- Diagnosis of dementia
- Diagnosis of chronic obstructive pulmonary disease (COPD) or other chronic respiratory illness
- Smoking history of ≥15 pack-years owing to possible undiagnosed COPD
- Moderate or severe cardiac disease (including New York Heart Association stages 4 or 5 congestive heart failure, because dyspnea among patients with severe heart failure is more likely to be attributable to their heart condition than their asthma)
- Dependence on assistance for medication administration
- Uncorrectable visual impairment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03646669
| United States, New York | |
| Albert Einstein College of Medicine/Yeshiva University | |
| Bronx, New York, United States, 10461 | |
| Jacobi Medical Center | |
| Bronx, New York, United States, 10461 | |
| Icahn School of Medicine at Mount Sinai | |
| New York, New York, United States, 10029 | |
| Principal Investigator: | Juan Wisnivesky, MD, MPH | Icahn School of Medicine at Mount Sinai |
| Responsible Party: | Juan P Wisnivesky, Professor of Medicine and Chief, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai |
| ClinicalTrials.gov Identifier: | NCT03646669 |
| Other Study ID Numbers: |
GCO 15-0667 R01HL131418 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 24, 2018 Key Record Dates |
| Last Update Posted: | March 2, 2021 |
| Last Verified: | February 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Older adults Asthma Symptom perception Self-management behaviors Medication adherence |
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |

